Glial fibrillary acidic protein
Glial fibrillary acidic protein (GFAP) is a structural protein primarily expressed in astrocytes and other glial cells within the central nervous system.
Glial fibrillary acidic protein (GFAP) is a structural protein primarily expressed in astrocytes and other glial cells within the central nervous system. It serves as a biomarker of glial cell activation and neuronal injury, making it valuable in the clinical assessment of various neurological disorders. GFAP is detectable in both cerebrospinal fluid (CSF) and serum, where elevated levels indicate disruption of the blood-brain barrier and glial pathology. As a marker of cellular stress and astrocytic response to injury, GFAP has emerged as an important diagnostic and prognostic tool in contemporary neuromedical practice, particularly when measured alongside complementary biomarkers such as neurofilament light chain (NfL) and ubiquitin C-terminal hydrolase L1 (UCH-L1). Its clinical utility spans traumatic brain injury, demyelinating diseases, autoimmune conditions, metabolic encephalopathies, and other acute and chronic neurodegenerative conditions.
- Blood biomarkers of brain damage in Transient Ischemic Attack: the role of plasma NfL and GFAP. PMID 42711449
Where the papers sit
26 papers study glial fibrillary acidic protein directly. The themes below are drawn from those 26.
-
Blood Biomarkers of Neurodegeneration : Combined GFAP, NfL and phosphorylated-tau measurements are being used to separate biological axes of cognitive decline and neurodegeneration rather than rely on a single marker. Longitudinal Alzheimer-spectrum, ALS and clinical cohorts, alongside platform comparisons, are pushing blood assays toward disease monitoring and outcome prediction. 9 papers · 34.6%
-
Blood Biomarkers of Brain Disease : Serum GFAP and NfL are moving toward ultrasensitive, multiplexed testing for stroke, traumatic injury, encephalopathy and neuromuscular disease. Prospective cohorts and new immunoassays repeatedly assess whether these markers can distinguish injury and support clinical stratification. 8 papers · 30.8%
-
Multiple Sclerosis Biomarkers : sNfL and sGFAP are moving toward routine multiple-sclerosis monitoring, with treatment stability, disability prognosis and retinal neuronal loss informing their clinical value. The work favors complementary markers: sGFAP adds prognostic information, while kappa free light chain supports diagnosis and NfL prognosis in autoimmune encephalitis. 5 papers · 19.2%
-
Blood Testing for Brain Injury : GFAP/UCH-L1 testing is moving from validation into routine emergency-department use for mild TBI, helping assess intracranial lesions and imaging needs. Cord-blood work extends neuronal-injury biomarker assessment beyond concussion, but implementation remains the dominant focus. 4 papers · 15.4%
Recent Findings on glial fibrillary acidic protein
Blood Biomarkers of Neurodegeneration: Plasma GFAP is increasingly paired with NF-L and phosphorylated-tau to distinguish astroglial, neuroaxonal, and tau-related biology. In amyotrophic lateral sclerosis, GFAP showed age-related and behavioural associations, whereas NF-L and pTAU181 reflected different motor-neuron processes 42049146Apr. In adults with Down syndrome, GFAP and NF-L increased longitudinally with age, while higher baseline levels were associated with subsequent cognitive decline 42679336Sep. Remote capillary GFAP measurements correlated with venous values, cognition, and function, although GFAP also appeared associated with vascular risk 42091863May. Plasma GFAP was higher in temporal lobe epilepsy with comorbid depression, while NF-L increased in temporal lobe epilepsy regardless of depression 42189430May. Platform comparisons found strong correlations but proportional bias, different decision cut-offs, and improved Alzheimer’s disease discrimination when GFAP and NF-L were added to a core Aβ and p-tau panel 41921527Apr.
Blood Biomarkers of Brain Disease: Plasma and serum GFAP are detecting astrocytic injury across transient ischemic attack, acute ischemic stroke, hepatic encephalopathy, anorexia nervosa, and traumatic brain injury cohorts. GFAP and NF-L were both elevated in MRI-negative transient ischemic attack, and their combination improved sensitivity while preserving specificity 42711449Sep. Serum GFAP increased after acute ischemic stroke, varied with sampling time, and was associated with hemorrhagic transformation, infection, disability, and survival 42295622Jun. In hepatic encephalopathy, NF-L showed stronger serum–cerebrospinal-fluid correlation and diagnostic performance than GFAP, while adolescent anorexia nervosa showed elevated GFAP and NF-L with less pronounced GFAP changes during treatment 42422896Jul42649149Aug. Myasthenia gravis studies disagree: one found higher GFAP values driven mainly by age, whereas another found no difference from controls or association with disease severity 42081930May42412876Jul. Click-chemistry and AI-enhanced nanophotonic assays are pushing GFAP toward ultrasensitive, rapid, multiplexed testing for traumatic brain injury and stroke subtyping 42610888Aug42166366May.
Multiple Sclerosis Biomarkers: Serum NF-L and GFAP are being evaluated as complementary markers for multiple sclerosis disease activity, progression, treatment stability, and clinical decision-making. The prospective NeuroFilMS study will test whether reporting serum NF-L changes therapeutic decisions, while retrospective GFAP measurements will assess additional information about progression and assay comparability 42419882Jul. Serum biomarkers remained stable after transition from intravenous to subcutaneous natalizumab, supporting their use in treatment monitoring 42332277Jun. Serum GFAP and retinal neuronal-loss measures are being combined as additive prognostic markers of disability, while reviews compare GFAP and NF-L with emerging cerebrospinal-fluid and serum candidates 42127333May42024828Apr. In autoimmune encephalitis, NF-L tracked disease severity and later disability, whereas GFAP had limited diagnostic and prognostic utility; intrathecal kappa free light chain provided higher diagnostic sensitivity 42546229Aug.
Blood Testing for Brain Injury: GFAP combined with UCHL1 is moving into emergency-department pathways for mild traumatic brain injury. In routine use, a negative test helped avoid computed tomography in many patients, and every detected intracranial lesion occurred after a positive test 42599452Aug. A separate implementation study evaluated the same biomarkers as negative predictors for excluding brain injury, while the IMPACTS-BRAINI protocol is assessing their integration into standardized pathways and effects on CT use and emergency-department time 42340459Jun42315262Jun. Umbilical cord-blood measurements extended GFAP and UCHL1 assessment to fetal vulnerability during maternal sleep-disordered breathing, but GFAP did not differ broadly between exposure groups 42472855Jul.
Glial Fibrillary Acidic Protein (GFAP)
Written from 26 PubMed abstracts, each one cited by PMID above. Published: 2026-08-18. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.